Development of CAR-T cell based on a newly identified tumor antigen
MJ Cellbio – Beyond New Horizon
General CAR-T
T cells engineered to attack and destroy only cancer cells by introducing chimeric antigen receptor (CAR) recognizing the antigens on tumor cells.
What makes MJCellBio CAR-T therapy different from others
-
CAR-T using a physiological ligand instead of antibody based scFv
- The binding affinity to the tumor associated antigen is higher than general scFv.
- In case of CAR-T cells based on antibodies (scFv), the variation in the binding sites (epitope) may have significant adverse effects on the function of CAR-T cells.
- Our ligand based CAR is relatively easier to adjust binding affinity to the target antigen to ensure safety by decreasing on-target off-tumor cytotoxicity.
CAR-T Treatment
* LV : Lentivirus gene delivery system
CAR-T Cell Mediated Cytotoxicity
